fluocinonide and Carcinoma, Epidermoid

fluocinonide has been researched along with Carcinoma, Epidermoid in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Aung, PP; Curry, JL; Duke, TC; Glitza Oliva, IC; Ledesma, DA; Marques-Piubelli, ML; Nagarajan, P; Nelson, KC; Prieto, VG; Tetzlaff, MT; Torres-Cabala, CA; Wistuba, II	1
Chainani-Wu, N; Lozada-Nur, F; Mayer, P; Silverman, S; Watson, JJ	1

Other Studies

2 other study(ies) available for fluocinonide and Carcinoma, Epidermoid

Article	Year
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. Journal of cutaneous pathology, 2020, Volume: 47, Issue:10 Topics: Acitretin; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dermatitis; Drug Eruptions; Drug Therapy, Combination; Exportin 1 Protein; Female; Fluocinonide; Glucocorticoids; Humans; Hypertrophy; Immune Checkpoint Inhibitors; Karyopherins; Keratolytic Agents; Lichenoid Eruptions; Melanoma; Programmed Cell Death 1 Receptor; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Triamcinolone	2020
Oral lichen planus: patient profile, disease progression and treatment responses. Journal of the American Dental Association (1939), 2001, Volume: 132, Issue:7 Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chronic Disease; Clobetasol; Disease Progression; Female; Fluocinonide; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppressive Agents; Lichen Planus, Oral; Male; Middle Aged; Mouth Neoplasms; Prednisone; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome	2001

Article

Year

Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.

Journal of cutaneous pathology, 2020, Volume: 47, Issue:10

Topics: Acitretin; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dermatitis; Drug Eruptions; Drug Therapy, Combination; Exportin 1 Protein; Female; Fluocinonide; Glucocorticoids; Humans; Hypertrophy; Immune Checkpoint Inhibitors; Karyopherins; Keratolytic Agents; Lichenoid Eruptions; Melanoma; Programmed Cell Death 1 Receptor; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Triamcinolone

2020

Oral lichen planus: patient profile, disease progression and treatment responses.

Journal of the American Dental Association (1939), 2001, Volume: 132, Issue:7

Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chronic Disease; Clobetasol; Disease Progression; Female; Fluocinonide; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppressive Agents; Lichen Planus, Oral; Male; Middle Aged; Mouth Neoplasms; Prednisone; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome

2001